/ /

LATEST

Optimizing CPC treatment outcomes with built-in transilluminationA new probe offers combined transillumination and laser fiber for targeted transscleral cyclophotocoagulation. Steven D. Vold, MD, shares some of his clinical experience.
Posterior IOLs effective in keratoconusPosterior chamber phakic IOLs can correct refractive errors associated with keratoconus and can also be combined with other surgical techniques when necessary, according to researchers.
The importance of being honestOne of the biggest challenges for ophthalmologists, especially in the field of refractive surgery, is to define ourselves (in professional terms) and set our goals.
ECP provides primary secondary therapy option for glaucomaFor 20 years I have effectively employed endoscopic cyclophotocoagulation (ECP) as a primary or secondary line of glaucoma treatment. ECP is a minimally invasive glaucoma surgical (MIGS) option capable of reducing IOP in the majority of patients and can potentially eliminate the need for drainage surgery, including trabeculectomy (trab) and glaucoma drainage devices (GDDs).
Laser trabeculoplasty suitable for all open-angle glaucoma patientsProstaglandin-based topical therapy has been the ‘go-to treatment’ for open-angle glaucoma for decades. In contrast, laser trabeculoplasty has conventionally remained reserved for patients unresponsive or unable to adhere to medication-based therapy.
New molecule enhances effect of anti-VEGF therapy for DMEActivation of Tie2–as a result of subcutaneous administration of AKB-9778 (Aerpio Therapeutics) in combination with an anti-vascular endothelial growth factor (anti-VEGF) therapy–enhances the effect of an anti-VEGF drug on diabetic macular edema (DME).
Insights from anti-VEGF pivotal DME trialsAnalyses of data collected in the RISE/RIDE and VIVID/VISTA clinical trials provide important messages about the efficacy and safety of ranibizumab (Lucentis, Genentech) and aflibercept (Eylea, Regeneron) for treatment of diabetic macular edema (DME).
Endocryotherapy shows potential for hemangioblastoma
Endocryotherapy shows potential for hemangioblastomaEndocryotherapy is a good treatment option for patients with larger retinal angiomatous tumors.
NRTIs hold promise for preventing or treating AMDNucleoside-reverse, transcriptase inhibitors (NRTIs) or their derivatives could one day be used to prevent or treat age-related macular degeneration (AMD), according to Jayakrishna Ambati, MD.
Sustained-release dexamethasone products demonstrate positive results in pivotal trials

Poll

View Results